AACR Immuno-Oncology Conference (AACR IO) 2026 was held in Los Angeles from February 18-21, with the theme of “Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy”. The conference featured talks on basic, translational, and clinical research in immunology, inflammation, and immunotherapies for cancer, with 600+ scientists in attendance.
→ Biointron’s Highlighted Points:
Increasing emphasis on T-cell–redirecting antibodies, particularly CD3-based bispecifics, across both hematologic and solid tumor indications, highlighted in dedicated sessions on novel T-cell engagers.
Clinical-stage evaluation of DLL3/CD3 bispecific antibodies demonstrates activity across heterogeneous antigen expression levels, indicating a shift toward less restrictive target density requirements.
Emergence of multi-target cell therapies (e.g., bispecific CAR constructs such as CART19/20) reflects parallel design principles with antibody-based multispecifics, reinforcing the convergence of antibody and cell therapy engineering strategies.
Increased focus on mitigating toxicity through conditional activation and spatial targeting, including anchored agonist systems such as 4-1BB-directed constructs that localize immune activation within the tumor microenvironment.
Engineering efforts prioritize improved synapse formation, reduced cytokine release, and enhanced persistence of immune activation, indicating maturation of T-cell engager design beyond first-generation formats.
Bispecific Antibody Expression →
Continued expansion of checkpoint targets, with LAG-3 highlighted as a clinically relevant third checkpoint exhibiting synergistic activity with PD-1 blockade.
Development of non-canonical checkpoint strategies, including glyco-immune checkpoint blockade using antibody–lectin chimeras, indicating exploration of post-translational modifications as immune regulatory axes.
PSGL-1 blockade emerges as a novel antibody-mediated mechanism to overcome resistance to PD-1 inhibitors, particularly in melanoma and pancreatic cancer models.
Increased attention to intracellular and tumor-intrinsic pathways (e.g., neddylation, epigenetic regulators) that influence checkpoint sensitivity, creating opportunities for combination therapies involving antibodies and small molecules.
Identification of distinct T cell subsets (e.g., tumor-resident memory populations) regulating response to CTLA-4 and PD-1 blockade suggests the need for antibody strategies tailored to specific immune cell phenotypes.
Strong focus on modulating myeloid cell populations, including STING-mediated reprogramming of suppressive myeloid cells to enhance responsiveness to antibody-based immunotherapies.
Antibody-compatible approaches targeting macrophages and innate immune compartments, including IL-12–armored constructs and anti-macrophage CAR-T analogs, indicate cross-platform design principles.
Spatially resolved analyses of the TME identify interferon-driven niches and antigen presentation gradients as determinants of therapeutic response, informing antibody target selection and patient stratification.
Increasing interest in tertiary lymphoid structures (TLS) as sites of antibody-mediated immune activation, with efforts to induce TLS formation via STING and lymphotoxin pathways.
Integration of antibody therapies with metabolic and epigenetic reprogramming strategies to reverse immune suppression within the TME, including modulation of PRMT5 and TET1 pathways.
Development of antibody-lectin chimeras introduces a new class of biologics capable of targeting glycosylation-dependent immune checkpoints, expanding beyond protein-protein interaction paradigms.
Anchored cytokine and co-stimulatory receptor agonist antibodies (e.g., 4-1BB-targeted constructs) demonstrate improved safety profiles through localized activation, addressing systemic toxicity limitations.
Increasing incorporation of conditional activation mechanisms, including tumor-restricted activation and protease-sensitive designs, although not always explicitly labeled, is reflected in multiple engineering-focused sessions.
Expansion of antibody functionality to include immune-modulatory payload delivery and signaling control, paralleling trends in antibody-drug conjugates but applied to immunostimulation.
Growing overlap between antibody engineering and synthetic biology, particularly in the design of programmable immune modulators discussed in AI-driven protein engineering sessions.
Integration of systems immunology approaches to map immune cell interactions and predict response to antibody therapies, including multiscale modeling of tumor ecosystems.
Use of spatial multi-omics and plasma proteomics to identify biomarkers predictive of response to checkpoint inhibitors and antibody-based combinations.
Application of artificial intelligence to antibody and protein design, including generative models for immune modulators and chromatin-guided gene expression control.
Increasing reliance on data-driven approaches to optimize antibody affinity, specificity, and functional activity within complex immune environments.
Movement toward closed-loop design systems where computational modeling informs antibody engineering, followed by rapid experimental validation in relevant tumor models.
Antibody Developability Assessment →
Thank you to everyone who visited our booth at AACR IO 2026 to learn about our services! We had a fantastic time chatting with you and how it can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com or visit our website at www.biointron.com.
March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and a……
Clinical drug development remains associated with a high failure rate, primarily……
Read on for the key trends of the NextGen Biomed 2026 conference held in London ……
Biointron’s Networking Lunch (At the Table: Antibody Discovery) was held at Cata……
You can also contact us on the Scientist and Science Exchange marketplaces.
